CN103304490B - Method for separating and purifying five purine and pyrimidine bases from trichosanthes bark - Google Patents
Method for separating and purifying five purine and pyrimidine bases from trichosanthes bark Download PDFInfo
- Publication number
- CN103304490B CN103304490B CN201310240459.4A CN201310240459A CN103304490B CN 103304490 B CN103304490 B CN 103304490B CN 201310240459 A CN201310240459 A CN 201310240459A CN 103304490 B CN103304490 B CN 103304490B
- Authority
- CN
- China
- Prior art keywords
- water
- methanol
- separation
- sample
- purification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title claims abstract description 10
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title claims description 23
- 241000218989 Trichosanthes Species 0.000 title abstract description 26
- 238000000926 separation method Methods 0.000 claims abstract description 40
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical group O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000000746 purification Methods 0.000 claims abstract description 19
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims abstract description 18
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000287 crude extract Substances 0.000 claims abstract description 13
- 239000011347 resin Substances 0.000 claims abstract description 13
- 229920005989 resin Polymers 0.000 claims abstract description 13
- 229940075420 xanthine Drugs 0.000 claims abstract description 9
- 229940104302 cytosine Drugs 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000003480 eluent Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000010829 isocratic elution Methods 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 102000011759 adducin Human genes 0.000 claims description 3
- 108010076723 adducin Proteins 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims 4
- 244000078912 Trichosanthes cucumerina Species 0.000 claims 4
- 230000000274 adsorptive effect Effects 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 abstract description 18
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract description 14
- 238000002953 preparative HPLC Methods 0.000 abstract description 13
- 238000001179 sorption measurement Methods 0.000 abstract description 11
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 abstract description 9
- 229940035893 uracil Drugs 0.000 abstract description 8
- 235000017788 Cydonia oblonga Nutrition 0.000 abstract description 5
- 239000000178 monomer Substances 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 150000003212 purines Chemical class 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 241000975594 Trichosanthes rosthornii Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及从瓜蒌皮中分离纯化5种嘌呤及嘧啶碱(胞嘧啶、尿嘧啶、次黄嘌呤、鸟嘌呤及黄嘌呤)的方法,是以瓜蒌皮为原料,经过下述步骤:(1)瓜蒌皮粗提物的制备;(2)大孔吸附树脂柱粗分离;(3)半制备型高效液相色谱分离纯化:将样品1和样品2分别用半制备型高效液相色谱进行分离纯化,流动相为甲醇-水,得到高纯度的胞嘧啶、尿嘧啶、次黄嘌呤、鸟嘌呤及黄嘌呤5种单体化合物。工艺过程绿色环保,对环境无严重危害,综合成本低。
The present invention relates to a method for separating and purifying 5 kinds of purines and pyrimidine bases (cytosine, uracil, hypoxanthine, guanine and xanthine) from the skin of Trichosanthes quinces, using the skins of Trichosanthes as raw materials, through the following steps: ( 1) Preparation of crude extract of Trichosanthes barbatus; (2) Coarse separation with macroporous adsorption resin column; (3) Separation and purification by semi-preparative high-performance liquid chromatography: Sample 1 and sample 2 were separated by semi-preparative high-performance liquid chromatography Separation and purification are carried out, the mobile phase is methanol-water, and five monomer compounds of cytosine, uracil, hypoxanthine, guanine and xanthine are obtained with high purity. The technological process is green and environmentally friendly, has no serious harm to the environment, and has low overall cost.
Description
技术领域 technical field
本发明属于化工领域,具体是涉及一种从中药瓜蒌皮中分离纯化5种嘌呤及嘧啶碱基(胞嘧啶、尿嘧啶、次黄嘌呤、鸟嘌呤及黄嘌呤)的方法。 The invention belongs to the field of chemical industry, and in particular relates to a method for separating and purifying five kinds of purine and pyrimidine bases (cytosine, uracil, hypoxanthine, guanine and xanthine) from the skin of the traditional Chinese medicine Trichosanthes quince.
背景技术 Background technique
瓜蒌皮为葫芦科栝楼属植物栝楼(Trichosanthes kirilowii Marim.)或双边栝楼(Trichosanthes rosthornii Harms.)的干燥成熟果皮,属于常用中药,具有润肺化痰、利气宽胸等功效,临床上广泛用于治疗痰热咳嗽、痰浊黄稠、咽痛、胸痛、吐血、衄血、便秘、痈疮肿毒等症。现代药理实验及临床实践表明瓜蒌皮具有扩张冠状动脉、增加冠脉血流量、提高心肌耐缺氧能力、降低血清胆固醇、抗菌、抗癌等多种药理作用,尤其是对心血管疾病具有很好的治疗作用。 Trichosanthes kirilowii Marim. or Trichosanthes rosthornii Harms. is the dried and mature peel of Trichosanthes kirilowii Marim. or Trichosanthes rosthornii Harms. Clinically, it is widely used in the treatment of phlegm-heat cough, phlegm turbid yellow thick, sore throat, chest pain, hematemesis, epistaxis, constipation, carbuncle sores and swollen toxins. Modern pharmacological experiments and clinical practice have shown that Trichosanthes peel has various pharmacological effects such as expanding coronary arteries, increasing coronary blood flow, improving myocardial hypoxia resistance, lowering serum cholesterol, antibacterial, and anticancer, especially for cardiovascular diseases. Good therapeutic effect.
核酸包含了生物遗传信息,嘌呤、嘧啶类生物碱基是构成核酸的重要组成部分,广泛参与遗传和代谢等多种生命活动,它们的代谢异常常引起诸多严重的疾病,如肾衰竭、痛风及男性不育等。次黄嘌呤是一种非常重要的生物嘌呤碱,具有降低血压、平喘、治疗痛风等药理活性,在人体内分布广泛,能够参与调节人体内的一些重要的生理机能,还可用于治疗各种原因所致的白细胞减少症、血小板减少症等疾病,国外还报道黄嘌呤、次黄嘌呤与肿瘤细胞的生长代谢关系密切。 Nucleic acid contains biological genetic information. Purine and pyrimidine alkaloids are important components of nucleic acid, and they are widely involved in various life activities such as heredity and metabolism. Their metabolic abnormalities often cause many serious diseases, such as kidney failure, gout and Male infertility etc. Hypoxanthine is a very important biological purine base, which has pharmacological activities such as lowering blood pressure, relieving asthma, and treating gout. It is widely distributed in the human body and can participate in the regulation of some important physiological functions in the human body. It can also be used to treat various Leukopenia, thrombocytopenia and other diseases caused by various causes, foreign countries have also reported that xanthine and hypoxanthine are closely related to the growth and metabolism of tumor cells.
现已有文献报道从瓜蒌皮中提取纯化嘌呤及嘧啶类生物碱基的方法。滕勇荣[瓜蒌皮和瓜蒌皮注射液化学成分研究,山东中医药大学硕士学位论文,2011年]利用反复硅胶柱层析、大孔吸附树脂柱色谱及制备型高效液相色谱等分离手段对瓜蒌皮的化学成分进行了研究,共得到7个化合物,其中包括3个核苷类成分(腺嘌呤、鸟嘌呤核苷及6-异次黄嘌呤核苷)。时岩鹏[栝楼化学成分的研究及其α-菠菜甾醇的含量测定(I),中草药,2002年1期]利用反复硅胶柱层析对栝楼的化学成分进行了研究,自石油醚部位、氯仿部位、正丁醇部位分离得到12个化合物,其中10个得到了鉴定,包括1种核苷类成分—尿嘧啶。刘岱琳[瓜蒌的抗血小板聚集活性成分研究. 中草药,2004年12期]利用抗血小板聚集的活性追踪方法,采用Sephadex LH-20柱色谱及反复硅胶柱色谱分离,自瓜蒌中分离得到7个化合物,其中包括1种核苷类成分—腺嘌呤核苷。 A method for extracting and purifying purine and pyrimidine alkaloids from Trichosanthes rind has been reported in the literature. Teng Yongrong [Study on the chemical composition of Gualoupi and Gualoupi injection, master's degree thesis of Shandong University of Traditional Chinese Medicine, 2011] using repeated silica gel column chromatography, macroporous adsorption resin column chromatography and preparative high performance liquid chromatography to separate the The chemical constituents of the skin of Trichosanthes L. were studied, and a total of 7 compounds were obtained, including 3 nucleoside components (adenine, guanosine and 6-isosinosine). Shi Yanpeng [Research on the chemical composition of Trichosanthes and the determination of α-spinasterol (I), Chinese herbal medicine, 2002, No. 1] using repeated silica gel column chromatography to study the chemical composition of Trichosanthes, from the petroleum ether part , chloroform, and n-butanol were separated to obtain 12 compounds, 10 of which were identified, including 1 nucleoside component—uracil. Liu Dailin [Study on the anti-platelet aggregation active ingredients of Trichosanthes trichosanthes. Chinese herbal medicine, 2004, No. 12] Using the anti-platelet aggregation activity tracking method, using Sephadex LH-20 column chromatography and repeated silica gel column chromatography, 7 compounds were isolated from Trichosanthes trichosanthes. Compounds, including a nucleoside component - adenosine.
上述方法主要存在的问题是:分离过程步骤较为繁琐,有时需要使用氯仿为萃取剂或 The main problem of the above-mentioned method is: the separation process step is comparatively loaded down with trivial details, needs to use chloroform sometimes as extraction agent or
洗脱剂,对人体和环境均有严重危害,而且得到的嘌呤及嘧啶碱基的种类少,生产周期较长,生产成本较高。 The eluent has serious harm to the human body and the environment, and the types of purine and pyrimidine bases obtained are few, the production cycle is long, and the production cost is high.
发明内容 Contents of the invention
本发明的目的在于克服现有技术的不足,提供一种操作简便、绿色环保、综合成本低、生产周期短的快速从中药瓜蒌皮中分离纯化嘌呤及嘧啶碱基的方法。 The purpose of the present invention is to overcome the deficiencies of the prior art, and provide a method for quickly separating and purifying purine and pyrimidine bases from the traditional Chinese medicine Trichosanthes quince, which is easy to operate, environmentally friendly, low in overall cost, and short in production cycle.
本发明的方案如下: The scheme of the present invention is as follows:
从中药瓜蒌皮中分离纯化嘌呤及嘧啶碱基的方法,其步骤为: The method for separating and purifying purine and pyrimidine bases from the peel of the traditional Chinese medicine Trichosanthes quince, the steps are:
(1)瓜蒌皮粗提物的制备:取粉碎好的瓜蒌皮药材,用水加热回流提取,提取液经减压浓缩至相对密度为1.2左右,向浓缩液中加入95%乙醇至乙醇的浓度为70%左右,静置72 h,过滤,取上层清液,减压浓缩得粗提物; (1) Preparation of the crude extract of Trichosanthes rind: Take the crushed medicinal material of Trichosanthes piscifolia, heat and reflux with water to extract, the extract is concentrated under reduced pressure to a relative density of about 1.2, and 95% ethanol to the concentration of ethanol is added to the concentrated solution. The concentration is about 70%, let it stand for 72 hours, filter, take the supernatant, and concentrate under reduced pressure to obtain the crude extract;
(2)大孔吸附树脂柱粗分离:将瓜蒌皮粗提物溶于水中,上HPD826型大孔吸附树脂柱进行层析,先用水进行洗脱,再用浓度为5%左右的乙醇-水溶液进行洗脱,分别收集水及5%左右的乙醇-水洗脱液,前者减压浓缩,得样品1,后者减压浓缩,得样品2; (2) Coarse separation with macroporous adsorption resin column: Dissolve the crude extract of Trichosanthes piperi in water, apply HPD826 macroporous adsorption resin column for chromatography, first elute with water, and then use ethanol with a concentration of about 5%- The aqueous solution was used for elution, and water and about 5% ethanol-water eluent were collected respectively. The former was concentrated under reduced pressure to obtain sample 1, and the latter was concentrated under reduced pressure to obtain sample 2;
(3)样品1的进一步分离纯化:将样品1用半制备型高效液相色谱进行分离纯化,色谱柱为YMC ODS-AQ柱,流动相为甲醇-水,检测波长为254 nm; (3) Further separation and purification of sample 1: The sample 1 was separated and purified by semi-preparative high performance liquid chromatography, the chromatographic column was YMC ODS-AQ column, the mobile phase was methanol-water, and the detection wavelength was 254 nm;
(4)样品2的进一步分离纯化:将样品2用半制备型高效液相色谱进行分离纯化,色谱柱为YMC ODS-AQ柱,流动相为甲醇-水,检测波长为254 nm; (4) Further separation and purification of sample 2: The sample 2 was separated and purified by semi-preparative high performance liquid chromatography, the chromatographic column was YMC ODS-AQ column, the mobile phase was methanol-water, and the detection wavelength was 254 nm;
收集目标组分馏分,将得到的馏分减压浓缩,即得到所要分离的单体化合物。 The fractions of the target components are collected, and the obtained fractions are concentrated under reduced pressure to obtain the monomer compound to be separated.
前面所述的方法,优选的方案是,步骤(1)加热回流提取时提取时间为1-3小时,提取次数为2-6次。更加优选的是,提取时间为1.5-2.5小时(优选2小时),提取次数为3-5次(优选4次)。 In the above-mentioned method, the preferred solution is that the extraction time in step (1) heating under reflux extraction is 1-3 hours, and the number of extractions is 2-6 times. More preferably, the extraction time is 1.5-2.5 hours (preferably 2 hours), and the extraction frequency is 3-5 times (preferably 4 times).
前面所述的方法,优选的方案是,步骤(3)流动相为 0-5%的甲醇-水洗脱液(优选2%),洗脱液流速为2.5-4.5 mL/min(优选3.5 mL/min)。 The method described above, the preferred scheme is that the mobile phase of step (3) is 0-5% methanol-water eluent (preferably 2%), and the eluent flow rate is 2.5-4.5 mL/min (preferably 3.5 mL /min).
前面所述的方法,优选的方案是,步骤(4)用甲醇-水洗脱液进行洗脱时,所用甲醇的质量浓度为2%-6%(优选4%)。洗脱液流速为2.5-4.5 mL/min(优选3.5 mL/min)。 In the aforementioned method, a preferred scheme is that when step (4) is eluted with methanol-water eluent, the mass concentration of methanol used is 2%-6% (preferably 4%). The eluent flow rate is 2.5-4.5 mL/min (preferably 3.5 mL/min).
前面所述的方法,优选的方案是,步骤(3)洗脱方式为甲醇-水梯度洗脱/2%甲醇-水等度洗脱/100%水等度洗脱/5%甲醇-水等度洗脱,优选的是,洗脱液流速为2.5-4.5 mL/min(优选3.5 mL/min)。 The method described above, the preferred solution is that the elution method of step (3) is methanol-water gradient elution/2% methanol-water isocratic elution/100% water isocratic elution/5% methanol-water, etc. Speed elution, preferably, the eluent flow rate is 2.5-4.5 mL/min (preferably 3.5 mL/min).
前面所述的方法,优选的方案是,步骤(4)分离纯化时的洗脱方式为6%甲醇-水等度洗脱/4%甲醇-水等度洗脱/2%甲醇-水等度洗脱/甲醇-水梯度洗脱,优选的是,洗脱液流速为2.5-4.5 mL/min(优选3.5 mL/min)。 For the method described above, the preferred scheme is that the elution method during the separation and purification of step (4) is 6% methanol-water isocratic elution/4% methanol-water isocratic elution/2% methanol-water isocratic elution Elution/methanol-water gradient elution, preferably, the eluent flow rate is 2.5-4.5 mL/min (preferably 3.5 mL/min).
本发明涉及从中药瓜蒌皮中分离纯化嘌呤及嘧啶碱基的方法,步骤为:(1)瓜蒌皮粗提物的制备:取粉碎好的瓜蒌皮药材,用水加热回流提取,提取液经减压浓缩至相对密度为1.2左右,向浓缩液中加入95%乙醇至乙醇的浓度为70%左右,静置72 h,过滤,取上层清液,减压浓缩得粗提物。(2)大孔吸附树脂柱粗分离:将瓜蒌皮粗提物溶于水中,上HPD826型大孔吸附树脂柱进行层析,先用水进行洗脱,再用浓度为5%左右的乙醇-水为洗脱液进行洗脱,分别收集水及5%左右的乙醇-水洗脱液,前者减压浓缩,得样品1,后者减压浓缩,得样品2。(3)样品1的进一步分离纯化:将样品1用半制备型高效液相色谱进行分离纯化,色谱柱为YMC ODS-AQ柱(250 mm×10 mm I. D., 10 μm,大连江申分离科技有限公司),流动相为甲醇-水,检测波长为254 nm。 (4)样品2的进一步分离纯化:将样品2用半制备型高效液相色谱进行分离纯化,色谱柱为YMC ODS-AQ柱(250 mm×10 mm I. D., 10 μm,大连江申分离科技有限公司),流动相为甲醇-水,检测波长为254 nm。 The invention relates to a method for separating and purifying purine and pyrimidine bases from the traditional Chinese medicine Trichosanthes peel, the steps are as follows: (1) Preparation of the crude extract of Trichosanthes peel: Take the crushed medicinal material of Trichosanthes peel, heat and reflux with water to extract, and extract Concentrate under reduced pressure to a relative density of about 1.2, add 95% ethanol to the concentrated solution until the concentration of ethanol is about 70%, let it stand for 72 hours, filter, take the supernatant, and concentrate under reduced pressure to obtain a crude extract. (2) Coarse separation with macroporous adsorption resin column: Dissolve the crude extract of Trichosanthes piperi in water, apply HPD826 macroporous adsorption resin column for chromatography, first elute with water, and then use ethanol with a concentration of about 5%- Water was used as the eluent for elution, and water and about 5% ethanol-water eluent were collected respectively. The former was concentrated under reduced pressure to obtain sample 1, and the latter was concentrated under reduced pressure to obtain sample 2. (3) Further separation and purification of sample 1: The sample 1 was separated and purified by semi-preparative high performance liquid chromatography, and the chromatographic column was a YMC ODS-AQ column (250 mm×10 mm I. D., 10 μm, Dalian Jiangshen Separation Technology Co., Ltd.), the mobile phase was methanol-water, and the detection wavelength was 254 nm. (4) Further separation and purification of sample 2: The sample 2 was separated and purified by semi-preparative high-performance liquid chromatography, and the chromatographic column was YMC ODS-AQ column (250 mm×10 mm I. D., 10 μm, Dalian Jiangshen Separation Technology Co., Ltd.), the mobile phase was methanol-water, and the detection wavelength was 254 nm.
本工艺过程绿色环保,对环境无严重危害,综合成本低。 The technological process is green and environmentally friendly, has no serious harm to the environment, and has low overall cost.
本发明从中药瓜蒌皮中分离纯化5种嘌呤及嘧啶碱基的方法,首先采用大孔吸附树脂柱粗分离,再用半制备型高效液相色谱法进行分离纯化,所得目标化合物纯度高,杂质含量极低,这一点可从图5-图9中看出。除此之外,还具有如下优势: The method of the present invention for separating and purifying five kinds of purine and pyrimidine bases from the rind of the traditional Chinese medicine Trichosanthes quinquefolium, first adopts a macroporous adsorption resin column for rough separation, and then uses semi-preparative high-performance liquid chromatography for separation and purification, and the obtained target compound has high purity, The impurity content is extremely low, which can be seen from Figures 5-9. In addition, it also has the following advantages:
(1)提取物经过大孔吸附树脂柱粗分离后可以除去大部分的杂质,使混合物的组成得到简化,可以为后续的分离工作降低难度,并且可以保护半制备型高效液相色谱柱不被污染,有效地延长了色谱柱的使用寿命。 (1) After the extract is roughly separated by a macroporous adsorption resin column, most of the impurities can be removed, the composition of the mixture is simplified, the difficulty of subsequent separation can be reduced, and the semi-preparative high-performance liquid chromatography column can be protected from being Contamination effectively prolongs the service life of the chromatographic column.
(2)使用半制备型高效液相色谱法两次分离纯化就可以同时得到胞嘧啶、尿嘧啶、次黄嘌呤、鸟嘌呤及黄嘌呤5种高纯度单体化合物,方法操作简单,效率高,工艺周期短,节省试剂,降低了生产成本。 (2) Five high-purity monomeric compounds of cytosine, uracil, hypoxanthine, guanine and xanthine can be obtained at the same time by using semi-preparative high-performance liquid chromatography for two separations and purifications. The method is simple to operate and high in efficiency. The process cycle is short, reagents are saved, and production costs are reduced.
(3)纯化过程中不使用对环境和人体危害大的氯仿等有机溶剂,大孔吸附树脂经再生后可以重复使用多次,绿色环保。 (3) Organic solvents such as chloroform, which are harmful to the environment and human body, are not used in the purification process. The macroporous adsorption resin can be reused many times after regeneration, which is green and environmentally friendly.
(4)优化了层析方法的条件(洗脱液的组成和流速),使化合物的纯度和效率都大为提高。 (4) The conditions of the chromatographic method (composition and flow rate of the eluent) were optimized, so that the purity and efficiency of the compound were greatly improved.
附图说明 Description of drawings
图1是样品1的高效液相色谱图。 Figure 1 is a high performance liquid chromatogram of sample 1.
图2是样品2的高效液相色谱图。 Figure 2 is a high performance liquid chromatogram of sample 2.
图3是样品1的半制备型高效液相色谱图。 Figure 3 is a semi-preparative high performance liquid chromatogram of sample 1.
图4是样品2的半制备型高效液相色谱图。 Figure 4 is a semi-preparative high performance liquid chromatogram of sample 2.
图5是胞嘧啶的高效液相色谱图及紫外光谱图。 Fig. 5 is the high performance liquid chromatogram and the ultraviolet spectrogram of cytosine.
图6是尿嘧啶的高效液相色谱图及紫外光谱图。 Fig. 6 is the high-performance liquid chromatogram and the ultraviolet spectrogram of uracil.
图7是次黄嘌呤的高效液相色谱图及紫外光谱图。 Figure 7 is a high performance liquid chromatogram and an ultraviolet spectrogram of hypoxanthine.
图8是鸟嘌呤的高效液相色谱图及紫外光谱图。 Figure 8 is a high performance liquid chromatogram and an ultraviolet spectrogram of guanine.
图9是黄嘌呤的高效液相色谱图及紫外光谱图。 Fig. 9 is a high-performance liquid chromatogram and an ultraviolet spectrogram of xanthine.
具体实施方式 Detailed ways
下面结合实施例和附图详细说明本发明的技术方案,但保护范围不被此限制。实施例中所用设备或原料皆可从市场获得。所用试剂均购自济南试剂总厂,所用水为去离子水。 The technical solutions of the present invention will be described in detail below in conjunction with the embodiments and drawings, but the scope of protection is not limited thereto. The equipment or raw materials used in the examples are all available from the market. All reagents used were purchased from Jinan General Reagent Factory, and the water used was deionized water.
实施例:从中药瓜蒌皮中分离纯化嘌呤及嘧啶碱基的方法,其步骤为: Embodiment: the method for separating and purifying purine and pyrimidine bases from the peel of the traditional Chinese medicine Trichosanthes quince, the steps are:
(1)瓜蒌皮粗提物的制备:瓜蒌皮药材经粉碎后,以水为溶剂加热回流提取4次,合并提取液,减压浓缩至相对密度为1.2左右,向浓缩液中加入95%乙醇至乙醇的浓度为70%左右,静置72 h,过滤,取上层清液,减压浓缩得粗提物。 (1) Preparation of the crude extract of Trichosanthes rind: after crushing the medicinal material of Trichosanthes trichosanthes, heat and reflux extraction with water for 4 times, combine the extracts, concentrate under reduced pressure to a relative density of about 1.2, and add 95 % ethanol until the concentration of ethanol is about 70%, let it stand for 72 h, filter, take the supernatant, and concentrate under reduced pressure to obtain the crude extract.
(2)大孔吸附树脂柱粗分离:将瓜蒌皮粗提物溶于水中,上HPD826型大孔吸附树脂柱进行层析,先用水进行洗脱,再用浓度为5%左右的乙醇-水溶液进行洗脱,分别收集水及5%左右的乙醇-水洗脱液,前者减压浓缩,得样品1,后者减压浓缩,得样品2。 (2) Coarse separation with macroporous adsorption resin column: Dissolve the crude extract of Trichosanthes piperi in water, apply HPD826 macroporous adsorption resin column for chromatography, first elute with water, and then use ethanol with a concentration of about 5%- The aqueous solution was eluted, and water and about 5% ethanol-water eluate were collected respectively. The former was concentrated under reduced pressure to obtain sample 1, and the latter was concentrated under reduced pressure to obtain sample 2.
(3)样品1的进一步分离纯化:将样品1用半制备型高效液相色谱进行分离纯化,色谱柱为YMC ODS-AQ柱(250 mm×10 mm I. D., 10 μm,大连江申分离科技有限公司),流动相为甲醇-水,检测波长为254 nm。 (3) Further separation and purification of sample 1: The sample 1 was separated and purified by semi-preparative high performance liquid chromatography, and the chromatographic column was a YMC ODS-AQ column (250 mm×10 mm I. D., 10 μm, Dalian Jiangshen Separation Technology Co., Ltd.), the mobile phase was methanol-water, and the detection wavelength was 254 nm. the
(4)样品2的进一步分离纯化:将样品2用半制备型高效液相色谱进行分离纯化,色谱柱为YMC ODS-AQ柱(250 mm×10 mm I. D., 10 μm,大连江申分离科技有限公司),流动相为甲醇-水,检测波长为254 nm。 (4) Further separation and purification of sample 2: The sample 2 was separated and purified by semi-preparative high-performance liquid chromatography, and the chromatographic column was YMC ODS-AQ column (250 mm×10 mm I. D., 10 μm, Dalian Jiangshen Separation Technology Co., Ltd.), the mobile phase was methanol-water, and the detection wavelength was 254 nm. the
收集目标组分馏分,将得到的馏分减压浓缩,即得到所要分离的单体化合物。 The fractions of the target components are collected, and the obtained fractions are concentrated under reduced pressure to obtain the monomer compound to be separated.
发明人通过使用不同浓度的甲醇作流动相,采用不同的洗脱方式,控制洗脱液的流速为2.5-4.5 mL/min(优选3.5 mL/min),优选出了实现本发明目的的纯化条件,有关实验结果如下: The inventor used different concentrations of methanol as the mobile phase, adopted different elution methods, and controlled the flow rate of the eluent to be 2.5-4.5 mL/min (preferably 3.5 mL/min), and optimized the purification conditions to achieve the purpose of the present invention , the relevant experimental results are as follows:
表一 样品1的半制备型高效液相色谱分离条件 Table 1 Semi-preparative HPLC separation conditions of sample 1
在实施例1中,采用5%甲醇-水为洗脱液等度洗脱,各成分洗脱时间较短,但相互之间分离效果不够理想,所得成分纯度较低。实施例2中采用2%甲醇-水为洗脱液等度洗脱,各成分之间分离良好,分离时间也较为适宜。实施例3中采用100%水为洗脱液等度洗脱,各成分分离良好,但分离时间太长。实施例4采用甲醇-水梯度洗脱,各成分分离良好,分离时间也可以,但洗脱液由于浓度变化导致回收再利用存在较大困难。 In Example 1, 5% methanol-water was used as the eluent for isocratic elution, and the elution time of each component was shorter, but the separation effect between them was not ideal, and the purity of the obtained components was low. In Example 2, 2% methanol-water was used as the eluent for isocratic elution, and the components were separated well, and the separation time was also relatively appropriate. In Example 3, 100% water was used as the eluent for isocratic elution, and the components were separated well, but the separation time was too long. Example 4 adopts methanol-water gradient elution, the components are separated well, and the separation time is also acceptable, but the recovery and reuse of the eluate is difficult due to concentration changes.
图3是当选用实施例2体系时的色谱图,由图3可见,各成分分离良好,分离时间也较为适宜。根据色谱图收集各峰组分,回收溶剂后,即可得到相应高纯度化合物。经高效液相色谱面积归一化法分析测试,实施例2所得到的各个组分的纯度很高,均在98%以上,这一点可从图5-图6中看出。 Fig. 3 is the chromatogram when the system of Example 2 is selected for use, as can be seen from Fig. 3, each component is well separated, and the separation time is also comparatively suitable. The peak components are collected according to the chromatogram, and the corresponding high-purity compound can be obtained after recovering the solvent. After analysis and testing by the high performance liquid chromatography area normalization method, the purity of each component obtained in Example 2 is very high, all above 98%, which can be seen from Figures 5-6.
表二 样品2的半制备型高效液相色谱分离条件 Table 2 The semi-preparative high performance liquid chromatography separation conditions of sample 2
在实施例5中,采用6%甲醇-水为洗脱液等度洗脱,各成分洗脱时间较短,但相互之间分离效果不够理想,所得成分纯度较低。实施例6中采用4%甲醇-水为洗脱液等度洗脱,各成分之间分离良好,分离时间也较为适宜。实施例7中采用2%甲醇-水为洗脱液等度洗脱,各成分分离良好,但分离时间太长。实施例8采用甲醇-水梯度洗脱,各成分分离良好,分离时间也可以,但洗脱液由于浓度变化导致回收再利用存在较大困难。 In Example 5, 6% methanol-water was used as the eluent for isocratic elution, and the elution time of each component was shorter, but the separation effect between them was not ideal, and the purity of the obtained components was low. In Example 6, 4% methanol-water was used as the eluent for isocratic elution, and the components were separated well, and the separation time was also relatively appropriate. In Example 7, 2% methanol-water was used as the eluent for isocratic elution, and the components were separated well, but the separation time was too long. Example 8 adopts methanol-water gradient elution, the components are separated well, and the separation time is also acceptable, but the recovery and reuse of the eluate is difficult due to concentration changes.
图4是当选用实施例6体系时的色谱图,由图4可见,各成分分离良好,分离时间也较为适宜。根据色谱图收集各峰组分,回收溶剂后,即可得到相应高纯度化合物。经高效液相色谱面积归一化法分析测试,实施例6所得到的各个组分的纯度很高,均在98%以上,这一点可从图7-图9中看出。 Fig. 4 is the chromatogram when selecting embodiment 6 system for use, as can be seen from Fig. 4, each component is separated well, and separation time is also comparatively suitable. The peak components are collected according to the chromatogram, and the corresponding high-purity compound can be obtained after recovering the solvent. After analysis and testing by the high performance liquid chromatography area normalization method, the purity of each component obtained in Example 6 is very high, all above 98%, which can be seen from Figures 7-9.
根据核磁共振氢谱和碳谱的测试,对所得峰组分进行鉴定,得到了胞嘧啶、尿嘧啶、次黄嘌呤、鸟嘌呤及黄嘌呤。经现代波谱数据证实所提取纯化得到的5个化合物的结构式如下: According to the test of H NMR spectrum and C NMR spectrum, the obtained peak components were identified, and cytosine, uracil, hypoxanthine, guanine and xanthine were obtained. The structural formulas of the extracted and purified five compounds confirmed by modern spectral data are as follows:
5种化合物的鉴定结果如下: The identification results of the five compounds are as follows:
化合物I(胞嘧啶):1H-NMR(400 MHz,DMSO-d6)δ ppm:10.47(1H,br s,1-H),7.32(1H,d,J=6.8 Hz,6-H),7.04(2H,br s,4-NH2),5.57(1H,d,J=6.8 Hz,5-H)。13C-NMR(100 MHz,DMSO-d6)δ ppm:166.6(C-4),156.8(C-2),142.5(C-6),92.4(C-5)。 Compound I (cytosine): 1 H-NMR (400 MHz, DMSO-d 6 ) δ ppm: 10.47 (1H, br s, 1-H), 7.32 (1H, d, J = 6.8 Hz, 6-H) , 7.04 (2H, br s, 4-NH 2 ), 5.57 (1H, d, J =6.8 Hz, 5-H). 13 C-NMR (100 MHz, DMSO-d 6 ) δ ppm: 166.6 (C-4), 156.8 (C-2), 142.5 (C-6), 92.4 (C-5).
化合物II(尿嘧啶):1H-NMR(400 MHz,DMSO-d6)δ ppm:10.48(2H,br s,1-H,3-H),7.39(1H,d,J=7.6 Hz,H-6),5.44(1H,d,J=7.6 Hz,H-5)。13C-NMR(100 MHz,DMSO-d6)δ ppm:164.1(C-4),151.4(C-2),142.1(C-6),100.0(C-5)。 Compound II (uracil): 1 H-NMR (400 MHz, DMSO-d 6 ) δ ppm: 10.48 (2H, br s, 1-H, 3-H), 7.39 (1H, d, J = 7.6 Hz, H-6), 5.44 (1H,d, J =7.6 Hz, H-5). 13 C-NMR (100 MHz, DMSO-d 6 ) δ ppm: 164.1 (C-4), 151.4 (C-2), 142.1 (C-6), 100.0 (C-5).
化合物III(次黄嘌呤):1H-NMR(400 MHz,DMSO-d6)δ ppm:13.20(1H,br s,9-H),12.29(1H,br s,1-H),8.18(1H,s,2-H),8.11(1H,s,H-8)。13C-NMR(100 MHz,DMSO-d6)δ ppm:155.6(C-6),153.7(C-4),152.7(C-8),144.1(C-2),119.5(C-5)。 Compound III (hypoxanthine): 1 H-NMR (400 MHz, DMSO-d 6 ) δ ppm: 13.20 (1H, br s, 9-H), 12.29 (1H, br s, 1-H), 8.18 ( 1H, s, 2-H), 8.11 (1H, s, H-8). 13 C-NMR (100 MHz, DMSO-d 6 ) δ ppm: 155.6 (C-6), 153.7 (C-4), 152.7 (C-8), 144.1 (C-2), 119.5 (C-5) .
化合物IV(鸟嘌呤):1H-NMR(400 MHz,D2O)δ ppm:7.34(1H,s,8-H)。13C-NMR(100 MHz,D2O)δ ppm:155.8(C-6),149.1(C-4),147.2(C-2),136.7 (C-8),106.5(C-5)。 Compound IV (guanine): 1 H-NMR (400 MHz, D 2 O) δ ppm: 7.34 (1H, s, 8-H). 13 C-NMR (100 MHz, D 2 O) δ ppm: 155.8 (C-6), 149.1 (C-4), 147.2 (C-2), 136.7 (C-8), 106.5 (C-5).
化合物V(黄嘌呤):1H-NMR(400 MHz,D2O)δ ppm:7.35(1H,s,8-H)。 13C-NMR(100 MHz,D2O)δ ppm:155.4(C-6),152.2(C-2),150.4(C-4),141.6(C-8),106.9(C-5)。 Compound V (xanthine): 1 H-NMR (400 MHz, D 2 O) δ ppm: 7.35 (1H, s, 8-H). 13 C-NMR (100 MHz, D 2 O) δ ppm: 155.4 (C-6), 152.2 (C-2), 150.4 (C-4), 141.6 (C-8), 106.9 (C-5).
应当指出的是,具体实施方式只是本发明比较有代表性的例子,显然本发明的技术方案不限于上述实施例。还可以有很多变形。本领域的普通技术人员,从此文件中所公开提到或是联想到的,均应认为是本专利所要保护的范围。 It should be noted that the specific embodiments are only representative examples of the present invention, and obviously the technical solution of the present invention is not limited to the above-mentioned embodiments. Many variants are also possible. Those of ordinary skill in the art should consider the disclosure, mention or association of this document as the scope of protection of this patent.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310240459.4A CN103304490B (en) | 2013-06-18 | 2013-06-18 | Method for separating and purifying five purine and pyrimidine bases from trichosanthes bark |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310240459.4A CN103304490B (en) | 2013-06-18 | 2013-06-18 | Method for separating and purifying five purine and pyrimidine bases from trichosanthes bark |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103304490A CN103304490A (en) | 2013-09-18 |
CN103304490B true CN103304490B (en) | 2015-02-18 |
Family
ID=49130250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310240459.4A Active CN103304490B (en) | 2013-06-18 | 2013-06-18 | Method for separating and purifying five purine and pyrimidine bases from trichosanthes bark |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103304490B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105541944B (en) * | 2016-03-02 | 2017-12-26 | 上海上药第一生化药业有限公司 | The preparation method and its usage of chemical composition in Pericarpium Trichosanthis injection |
CN105646628B (en) * | 2016-03-02 | 2018-01-23 | 上海上药第一生化药业有限公司 | The preparation method and its usage of chemical composition in Pericarpium Trichosanthis injection |
CN105669806B (en) * | 2016-03-02 | 2018-01-23 | 上海上药第一生化药业有限公司 | The preparation method and its usage of chemical composition in Pericarpium Trichosanthis injection |
CN110330541B (en) * | 2019-05-22 | 2023-03-21 | 南阳师范学院 | Method for separating 5 '-guanine nucleotide and 5' -cytosine nucleotide |
CN111603499A (en) * | 2020-05-22 | 2020-09-01 | 甘肃岷海医药科技有限公司 | Traditional Chinese medicine for preventing and treating cancer and preparation method thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62108813A (en) * | 1985-11-06 | 1987-05-20 | Tsumura Juntendo Inc | Inhibitor of blood platelet aggregation |
US7618657B2 (en) * | 2003-02-21 | 2009-11-17 | Ultra Biotech Limited | Active ingredients preparation and single compound purification from traditional Chinese herbal medicine Fructus Trichosanthis and uses thereof |
CN100408999C (en) * | 2005-07-12 | 2008-08-06 | 天津农学院 | Determination method of balsum pear saponin |
CN101152233B (en) * | 2006-09-25 | 2010-10-13 | 山东轩竹医药科技有限公司 | Pharmaceutical composition of snakegourd fruit and folium ginkgo |
-
2013
- 2013-06-18 CN CN201310240459.4A patent/CN103304490B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN103304490A (en) | 2013-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103304613B (en) | A kind of method of separation and purification 4 kinds of ucleosides chemical compositions from Snakegourd Peel | |
CN101735231B (en) | Method for extracting purified dendrobine from dendrobium stem | |
CN103304490B (en) | Method for separating and purifying five purine and pyrimidine bases from trichosanthes bark | |
CN102875562B (en) | Method for preparing psoralen and isopsoralen or extract containing psoralen and isopsoralen | |
CN102846784B (en) | Aquatic extract of vine vine, its preparation method and use | |
CN103641718B (en) | Method for separating and purifying chlorogenic acid and 3,5-dicaffeoylquinic acid from honeysuckle flower | |
CN102285994B (en) | Method for separating and purifying fangchinoline and tetrandrine from stephania tetrandra | |
CN102228515B (en) | Separation and enrichment method of total flavones and total alkaloids of Lotus Plumule | |
CN102070485B (en) | Method for Separating and Purifying Active Ingredient Golden Amino Alcohol Ester from Clematis paniculata, a Chinese Medicinal Material | |
CN108218948B (en) | Preparation method of sodium aescinate | |
CN104557834B (en) | A kind of isolated and purified pinocembrin, Chrysin and method of Galangin from China's Water extracts of propolis | |
WO2012061984A1 (en) | Method for preparing albiflorin and paeoniflorin | |
CN103304611B (en) | A kind of method of separation and purification 3 kinds of flavonoid glycosides from Snakegourd Peel | |
CN103342689B (en) | Method for separation and purification of luteolin, apigenin and diosmetin in trichosanthes peel | |
CN102526127A (en) | Flash type extraction method for active constituents in cordyceps militaris | |
CN109879919B (en) | A kind of method for separating and preparing three kinds of flavonoid glycosides from jujube seed | |
CN104327066B (en) | Method for rapidly and efficiently extracting carboline alkaloids | |
CN105017273A (en) | Method for extracting, separating and purifying psoralen and isopsoralen from fructus psoraleae | |
CN106188198B (en) | A kind of method of cAMP in high efficiency extraction jujube | |
CN107417692A (en) | A kind of method of purification of chlorinated nitidine | |
CN105294789B (en) | A kind of preparation method of high-purity salidroside | |
CN105016982B (en) | A method for extracting, separating and purifying honokiol and magnolol from magnolia bark | |
CN117815351A (en) | Preparation method of lung-heat clearing and toxin expelling granule | |
CN103965276B (en) | The method of fast separating and purifying monomeric compound from Lindley Eupatorium Herb | |
CN104557520B (en) | A method for separating and purifying caffeic acid, ferulic acid and isoferulic acid from Chinese propolis water extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICIN Free format text: FORMER OWNER: LIAOCHENG UNIVERSITY Effective date: 20150106 Owner name: SHANGHAI NO.1 BIO-CHEMICAL PHARMACETICAL INDUSTRY Effective date: 20150106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Aifeng Inventor after: Sun Ailing Inventor after: Liu Renmin Inventor after: Zhang Yongqing Inventor after: Huang Zhenhui Inventor before: Li Aifeng Inventor before: Zhang Yongqing Inventor before: Liu Renmin Inventor before: Sun Ailing |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI AIFENG ZHANG YONGQING LIU RENMIN SUN AILING TO: LI AIFENG SUN AILING LIU RENMIN ZHANG YONGQING HUANG ZHENHUI Free format text: CORRECT: ADDRESS; FROM: 252059 LIAOCHENG, SHANDONG PROVINCE TO: 250300 JINAN, SHANDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150106 Address after: 250300, 4655, University Road, Changqing District, Shandong, Ji'nan Applicant after: Shandong University of Traditional Chinese Medicine Applicant after: Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd. Applicant after: Liaocheng University Address before: 252059 Hunan Road, Dongchangfu, Shandong, No. 1, Applicant before: Liaocheng University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |